Thales Helps Microsoft Customers Protect Their Sensitive Data in the Cloud
16.3.2021 12:00:00 EET | Business Wire | Press release
Thales announces a new data protection capability for Microsoft customers to benefit from the power of the full range of Microsoft 365 applications while protecting sensitive data in the cloud and meeting major data privacy regulations and requirements.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210316005009/en/
Copyright Thales
Designed for companies that operate in highly-regulated sectors such as financial services and healthcare, they can now leverage Thales Luna Hardware Security Modules (HSMs) with Double Key Encryption for Microsoft 365 and comply with regulations such as the EU General Data Protection Regulation (GDPR), the Health Insurance Portability and Accountability Act (HIPAA), and the recommendations from the European Data Protection Board (EDPR) following the Schrems II ruling.
Securing Data in the Era of Remote Working and Increased Privacy Regulations
Today’s remote working environment relies heavily on the collaborative sharing of information, challenging organisations to maintain the security of confidential data and regulatory compliance while driving employee productivity. For organisations in highly regulated industries such as financial services, governments, and healthcare, their sensitive data requires the highest level of control and security. The integration of Luna HSMs with Double Key Encryption for Microsoft 365 delivers the protection required to protect highly sensitive data and meet unique regulatory requirements.
“The premise of remote working is no longer a perk reserved for a select few, but now the default operating model for many companies,” said Imran Mohiuddin, DKE partner director at Microsoft. “Our collaboration and productivity tools for Microsoft 365 customers are designed to enable companies to thrive in any situation. A key part in enabling this to happen though is ensuring they have the best security and compliance solutions when it comes to protecting sensitive data. Our Double Key Encryption integration with Thales enables customers who have enhanced data protection requirements, compliance obligations and regulatory restrictions to protect their highly sensitive information. By having full control of their encryption keys, customers can be certain that no third-party has access to their unencrypted data -- including Microsoft. Security should never be something that holds companies back in this remote era and from moving their sensitive information to the cloud, and with Thales, we’re ensuring it won’t for our customers.”
Thales has integrated its industry-leading Luna HSMs with Microsoft Double Key Encryption for Microsoft 365. This allows customers to protect their most confidential or sensitive data while maintaining control of their encryption keys in the cloud. The solution works by using two keys to protect data. One key is managed securely by the customer via the Luna HSM and a second key in Microsoft’s control. To view the data, one must have access to both keys, meaning it can’t be used without the customer’s permission.
“Our collaboration with Microsoft is designed to give peace of mind to customers when it comes to security, no matter where or what Microsoft applications they’re accessing,” said Todd Moore, vice president of encryption solutions at Thales. “The way we work has changed forever and in order to thrive, businesses have had to increasingly adapt and adopt collaborative applications. The integration of Thales Luna HSMs with Microsoft Double Key Encryption provides businesses with control over their encrypted data, in line with regulatory requirements, regardless of their industry.”
|
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions. Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
|
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005009/en/
Contact information
PRESS
Thales, Media Relations
Market
Laura Bandiera
+33 (0)7 64 48 51 64
laura.bandiera@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
